{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-127107","form_type":"8-K","ticker":"AKTX","cik":"0001541157","company_name":"Akari Therapeutics Plc","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.748165+00:00","generated_at":"2026-05-30T00:27:17.571336+00:00","sec_items":["1.01","2.01","3.01","3.02","5.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Akari Therapeutics completes merger with Peak Bio, secures $3.2M PIPE and $50M ELOC term sheet","bullets":["Merger closed; Peak Bio shareholders received 0.2935 Akari ADS per share, representing ~48.4% of combined entity on fully diluted basis.","Private placement of 1,713,402 ADSs+Warrants at $1.70/unit ($2.385 for insiders) for aggregate gross proceeds of $3.2M.","Entered term sheet for up to $50M equity line of credit with White Lion Capital over 3 years, subject to registration statement.","Nasdaq delisting risk resolved; company believes it now meets $2.5M stockholders' equity requirement post-merger.","Board changes: Wa'el Hashad and Donald Williams resigned; Hoyoung Huh (non-executive chairman), James Neal, Sandip Patel appointed."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-127107","json":"https://secwatch.observer/filing/0000950170-24-127107.json","markdown":"https://secwatch.observer/filing/0000950170-24-127107.md","text":"https://secwatch.observer/filing/0000950170-24-127107.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024127107/0000950170-24-127107-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024127107/aktx-20241113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:27:17.571336+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0034492ecf","claim":"Sandip Patel was appointed as Director at Akari Therapeutics Plc.","evidence_excerpt":"As previously disclosed, effective as of the Effective Time and pursuant to the terms of the Merger Agreement, the Akari Board appointed Hoyoung Huh, M.D., Ph. D, James Neal and Sandip Patel, each of whom were members of the board of directors of Peak Bio, to serve as directors for a term commencing upon the Effective Time.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024127107/0000950170-24-127107-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"03916e66c3","claim":"Wa'el Hashad resigned as Director at Akari Therapeutics Plc.","evidence_excerpt":"Wa’el Hashad and Donald Williams resigned as directors of Akari and any committees thereof.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024127107/0000950170-24-127107-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"617f84f255","claim":"Hoyoung Huh was appointed as non-executive chairman at Akari Therapeutics Plc.","evidence_excerpt":"Dr. Huh will serve as the non-executive chairman of the Akari Board as of the Effective Time.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024127107/0000950170-24-127107-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"non-executive chairman"}],"fact_type":"executive_change"},{"claim_id":"b6addf5e4b","claim":"Donald Williams resigned as Director at Akari Therapeutics Plc.","evidence_excerpt":"Wa’el Hashad and Donald Williams resigned as directors of Akari and any committees thereof.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024127107/0000950170-24-127107-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"eb8a3a2f16","claim":"James Neal was appointed as Director at Akari Therapeutics Plc.","evidence_excerpt":"As previously disclosed, effective as of the Effective Time and pursuant to the terms of the Merger Agreement, the Akari Board appointed Hoyoung Huh, M.D., Ph. D, James Neal and Sandip Patel, each of whom were members of the board of directors of Peak Bio, to serve as directors for a term commencing upon the Effective Time.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024127107/0000950170-24-127107-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}